FIELD: biotechnology.
SUBSTANCE: antibody or a fragment thereof suitable as a natriuretic peptide receptor agonist are disclosed. Antibody or a fragment thereof comprises a heterologous amino acid sequence included inside the CDR region, where said heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), brain natriuretic peptide (BNP) and C-terminal linker sequence (Ctls). Also presented a composition containing the antibody or its fragment, nucleic acid coding the antibody or its fragment, a host cell containing the above nucleic acid, a method for producing the antibody or its fragment.
EFFECT: invention provides preparing the natriuretic peptide receptor agonists with higher serum stability as compared to natural wild-type natriuretic peptides.
10 cl, 17 dwg, 11 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ATRIAL NATRIURETIC PEPTIDE GRAFTED ANTIBODIES | 2019 |
|
RU2822433C2 |
| C-TYPE NATRIURETIC PEPTIDE GRAFTED ANTIBODIES | 2019 |
|
RU2828786C2 |
| ANTI-CEACAM6 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2739163C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| THERAPEUTIC ANTI-CANCER NEOEPITOPE VACCINE | 2017 |
|
RU2782422C2 |
| NEONATAL Fc RECEPTOR BINDING AFFIMERS | 2020 |
|
RU2817008C1 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING VARIANT III OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2017 |
|
RU2751662C2 |
| ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137 | 2019 |
|
RU2826084C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
